-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of May 18, Steady Medical (300888) announced that it plans to use its own funds of 652 million yuan to acquire 655% of Hunan Ping An Medical Equipment, and use its own funds of 100 million yuan to unilaterally increase capital to Hunan Ping An Medical Equipme.
After the completion of the aforementioned transaction, Steady Medical will hold 670% of the equity of Hunan Ping An Medical Equipment after the capital increase and share expansion with a total investment of 752 million yu.
The main business of Hunan Ping An Medical Equipment is the research and development, production and sales of medical devices such as syringes, infusion sets, blood collection tubes, blood collection needles, and indwelling needl.
Steady Medical said that this acquisition is highly compatible with the company's strategy of creating a one-stop solution for medical consumabl.
With the advantages of both parties in customers, markets, products, R&D and production, scale and synergy will be form.
This is also the second time that Steady Medical has launched mergers and acquisitions since its acquisition of Longtai Medical on April 1 If the transaction is completed, it means that Steady Medical will enter the new track of injection and puncture products and fill the gap of its own related produc.
The announcement of the acquisition and capital increase of Hunan Ping An Medical Equipment shows that Hunan Ping An Medical Equipment was established in Changde, Hunan at the end of 201 In 2021, it will achieve an operating income of 360 million yuan and a net profit of 80326 million yuan; in the first quarter of 2022, it will achieve an operating income of 72666 million yuan and a net profit of 133314 million yu.
milli.
Considering the price-earnings ratio of listed companies producing puncture products such as syringes and infusion sets in the secondary market, after friendly negotiation by both parties, the overall price of 100% equity of Hunan Ping An Medical Equipment was determined to be RMB 995 million before the capital increa.
The net profit in 2021 is the base, and the price-earnings ratio of this transaction is about 170 tim.
At the same time, in order to support the future business development of Hunan Ping An Medical Equipment, Steady Medical signed a "Letter of Intent for Investment" with the People's Government of Li County, Hun.
As the main investor, Ping An Medical Equipment signed an investment agreement with the People's Government of Li County, Hunan Province, for the construction of medical equipment production lines, intelligent warehouses, R&D buildings and other supporting faciliti.
The total investment of the project is about 700 million yuan (the actual investment shall prevai.
The sources of funds include but are not limited to the daily operating funds of Hunan Ping An Medical Equipment, the company's capital increase, and the project loans that Hunan Ping An Medical Equipment has applied to financial institutio.
Acquisition and capital increase of Hunan Ping An Medical Equipment
It is a well-known trademark in China and a national high-tech enterpri.
"The Second Batch of Specialized, Special and New Little Giant Enterprise.
The company has 39 registration certificates for various medical devices, including 16 for the third category, 19 for the second category, and 4 for the first category, and 24 various patent certificat.
Its business scope covers at home and abroad, and it has a leading market share in the hospital market in Hunan Provin.
Regarding the scale and synergy effect after the acquisition, Steady Medical stated in the announcement that injection and puncture medical consumables are the largest category of low-value medical consumables in Chi.
This acquisition will fill the product gap of Steady Medical in this field and help Steady Medic.
It has become one of the most comprehensive companies in the domestic medical consumables product li.
According to the research and analysis of IBM and Medical Equipment Exchange, the domestic low-value medical consumables market will reach RMB 223 billion in 2025, of which puncture and injection products account for about 28%, which belongs to the largest catego.
Steady Medical's existing main business is medical Hygiene materials and dressings accounted for about 25%, belonging to the second largest catego.
Hunan Ping An Medical Equipment's syringes, infusion sets, indwelling needles, puncture kits and other products are matched with Robust Medical's operating room consumables and wound care products to form various combination packages and ultimately provide hospital users with one-stop customized solutions , to solve the pain points of patien.
Robust Medical can also rely on its own innovative R&D capabilities and intelligent manufacturing capabilities to help Hunan Ping An Medical Equipment continue to develop innovative products and solutions, and build a leading intelligent manufacturing facto.
Injection needles, puncture needles,e.
The unit price of each category is not high, but it is widely used and consumed in clinical practi.
According to the "Blue Book of Medical Devices in China (2021 Edition)" released by Medical Equipment Exchange, from 2018 to 2020, the market scale of low-value medical consumables in China will be 61 billion yuan, 77 billion yuan and 97 billion yuan respectively, of which injection and puncture products are in the low-value catego.
The medical consumables market accounts for the largest share, with a market share of 2
The scale in 2020 is about 22 billion yuan, and the compound annual growth rate from 2015 to 2020 is about 1
Looking forward to the future, the number of resident diagnoses will continue to increase, and new clinical applications and consumer-level application scenarios will increase, which will continue to drive the growth in demand for injection and puncture consumabl.
At the same time, Debon Securities mentioned in the research report that while the number of medical institutions in China continues to rise, surgical technology is also boomi.
Because puncture instruments play an important role in establishing channels, the usage scenarios are gradually being broadened, and will be more used in minimally invasive surgery and newer diagnosis and treatment scenarios in the futu.
In summary, it is expected that the market space in this field will further increa.
The first kick-off meeting of "Kehuang Capsules for the Treatment of Non-Alcoholic Fatty Liver Disease" was successfully held in Zhengzhou
After the completion of the aforementioned transaction, Steady Medical will hold 670% of the equity of Hunan Ping An Medical Equipment after the capital increase and share expansion with a total investment of 752 million yu.
Steady Medical said that this acquisition is highly compatible with the company's strategy of creating a one-stop solution for medical consumabl.
With the advantages of both parties in customers, markets, products, R&D and production, scale and synergy will be form.
This is also the second time that Steady Medical has launched mergers and acquisitions since its acquisition of Longtai Medical on April 1 If the transaction is completed, it means that Steady Medical will enter the new track of injection and puncture products and fill the gap of its own related produc.
The announcement of the acquisition and capital increase of Hunan Ping An Medical Equipment shows that Hunan Ping An Medical Equipment was established in Changde, Hunan at the end of 201 In 2021, it will achieve an operating income of 360 million yuan and a net profit of 80326 million yuan; in the first quarter of 2022, it will achieve an operating income of 72666 million yuan and a net profit of 133314 million yu.
milli.
Considering the price-earnings ratio of listed companies producing puncture products such as syringes and infusion sets in the secondary market, after friendly negotiation by both parties, the overall price of 100% equity of Hunan Ping An Medical Equipment was determined to be RMB 995 million before the capital increa.
The net profit in 2021 is the base, and the price-earnings ratio of this transaction is about 170 tim.
At the same time, in order to support the future business development of Hunan Ping An Medical Equipment, Steady Medical signed a "Letter of Intent for Investment" with the People's Government of Li County, Hun.
As the main investor, Ping An Medical Equipment signed an investment agreement with the People's Government of Li County, Hunan Province, for the construction of medical equipment production lines, intelligent warehouses, R&D buildings and other supporting faciliti.
The total investment of the project is about 700 million yuan (the actual investment shall prevai.
The sources of funds include but are not limited to the daily operating funds of Hunan Ping An Medical Equipment, the company's capital increase, and the project loans that Hunan Ping An Medical Equipment has applied to financial institutio.
Acquisition and capital increase of Hunan Ping An Medical Equipment
Enter the new track of injection and puncture category
Enter the new track of injection and puncture category Enter the new track of injection and puncture category Hunan Ping An Medical Equipment is mainly engaged in the research and development, production and sales of injection and puncture medical consumables (including syringes, infusion sets, blood collection tubes, blood collection needles, indwelling needles and other product.
It is a well-known trademark in China and a national high-tech enterpri.
"The Second Batch of Specialized, Special and New Little Giant Enterprise.
The company has 39 registration certificates for various medical devices, including 16 for the third category, 19 for the second category, and 4 for the first category, and 24 various patent certificat.
Its business scope covers at home and abroad, and it has a leading market share in the hospital market in Hunan Provin.
Regarding the scale and synergy effect after the acquisition, Steady Medical stated in the announcement that injection and puncture medical consumables are the largest category of low-value medical consumables in Chi.
This acquisition will fill the product gap of Steady Medical in this field and help Steady Medic.
It has become one of the most comprehensive companies in the domestic medical consumables product li.
According to the research and analysis of IBM and Medical Equipment Exchange, the domestic low-value medical consumables market will reach RMB 223 billion in 2025, of which puncture and injection products account for about 28%, which belongs to the largest catego.
Steady Medical's existing main business is medical Hygiene materials and dressings accounted for about 25%, belonging to the second largest catego.
Hunan Ping An Medical Equipment's syringes, infusion sets, indwelling needles, puncture kits and other products are matched with Robust Medical's operating room consumables and wound care products to form various combination packages and ultimately provide hospital users with one-stop customized solutions , to solve the pain points of patien.
Robust Medical can also rely on its own innovative R&D capabilities and intelligent manufacturing capabilities to help Hunan Ping An Medical Equipment continue to develop innovative products and solutions, and build a leading intelligent manufacturing facto.
Hunan Ping An Medical Equipment is mainly engaged in the research and development, production and sales of injection and puncture medical consumables (including syringes, infusion sets, blood collection tubes, blood collection needles, indwelling needles and other product.It is a well-known trademark in China and a national high-tech enterpri.
"The Second Batch of Specialized, Special and New Little Giant Enterprise.
The company has 39 registration certificates for various medical devices, including 16 for the third category, 19 for the second category, and 4 for the first category, and 24 various patent certificat.
Its business scope covers at home and abroad, and it has a leading market share in the hospital market in Hunan Provin.
Regarding the scale and synergy effect after the acquisition, Steady Medical stated in the announcement that injection and puncture medical consumables are the largest category of low-value medical consumables in Chi.
This acquisition will fill the product gap of Steady Medical in this field and help Steady Medic.
It has become one of the most comprehensive companies in the domestic medical consumables product li.
According to the research and analysis of IBM and Medical Equipment Exchange, the domestic low-value medical consumables market will reach RMB 223 billion in 2025, of which puncture and injection products account for about 28%, which belongs to the largest catego.
Steady Medical's existing main business is medical Hygiene materials and dressings accounted for about 25%, belonging to the second largest catego.
Hunan Ping An Medical Equipment's syringes, infusion sets, indwelling needles, puncture kits and other products are matched with Robust Medical's operating room consumables and wound care products to form various combination packages and ultimately provide hospital users with one-stop customized solutions , to solve the pain points of patien.
Robust Medical can also rely on its own innovative R&D capabilities and intelligent manufacturing capabilities to help Hunan Ping An Medical Equipment continue to develop innovative products and solutions, and build a leading intelligent manufacturing facto.
It is a well-known trademark in China and a national high-tech enterpri.
"The Second Batch of Specialized, Special and New Little Giant Enterprise.
The company has 39 registration certificates for various medical devices, including 16 for the third category, 19 for the second category, and 4 for the first category, and 24 various patent certificat.
Its business scope covers at home and abroad, and it has a leading market share in the hospital market in Hunan Provin.
Regarding the scale and synergy effect after the acquisition, Steady Medical stated in the announcement that injection and puncture medical consumables are the largest category of low-value medical consumables in Chi.
This acquisition will fill the product gap of Steady Medical in this field and help Steady Medic.
It has become one of the most comprehensive companies in the domestic medical consumables product li.
According to the research and analysis of IBM and Medical Equipment Exchange, the domestic low-value medical consumables market will reach RMB 223 billion in 2025, of which puncture and injection products account for about 28%, which belongs to the largest catego.
Steady Medical's existing main business is medical Hygiene materials and dressings accounted for about 25%, belonging to the second largest catego.
Hunan Ping An Medical Equipment's syringes, infusion sets, indwelling needles, puncture kits and other products are matched with Robust Medical's operating room consumables and wound care products to form various combination packages and ultimately provide hospital users with one-stop customized solutions , to solve the pain points of patien.
Robust Medical can also rely on its own innovative R&D capabilities and intelligent manufacturing capabilities to help Hunan Ping An Medical Equipment continue to develop innovative products and solutions, and build a leading intelligent manufacturing facto.
More application scenarios drive demand growth
More application scenarios drive demand growth More application scenarios drive demand growth It is understood that common injection and puncture devices include disposable sterile syringes and their rubber stoppers, disposable sterile injection needles, disposable intravenous infusion needles, disposable fiber-optic needles, intravenous indwelling needles, and disposable pharmaceutical preparatio.
Injection needles, puncture needles,e.
The unit price of each category is not high, but it is widely used and consumed in clinical practi.
It is understood that common injection and puncture devices include disposable sterile syringes and their rubber stoppers, disposable sterile injection needles, disposable intravenous infusion needles, disposable fiber-optic needles, intravenous indwelling needles, and disposable pharmaceutical preparatio.Injection needles, puncture needles,e.
The unit price of each category is not high, but it is widely used and consumed in clinical practi.
Injection needles, puncture needles,e.
The unit price of each category is not high, but it is widely used and consumed in clinical practi.
In the research report of Kindly, a leading listed company in the domestic injection and puncture industry released by Huaan Securities, it is mentioned that injection and puncture consumables are a large category of low-value consumabl.
According to the "Blue Book of Medical Devices in China (2021 Edition)" released by Medical Equipment Exchange, from 2018 to 2020, the market scale of low-value medical consumables in China will be 61 billion yuan, 77 billion yuan and 97 billion yuan respectively, of which injection and puncture products are in the low-value catego.
The medical consumables market accounts for the largest share, with a market share of 2
The scale in 2020 is about 22 billion yuan, and the compound annual growth rate from 2015 to 2020 is about 1
Looking forward to the future, the number of resident diagnoses will continue to increase, and new clinical applications and consumer-level application scenarios will increase, which will continue to drive the growth in demand for injection and puncture consumabl.
At the same time, Debon Securities mentioned in the research report that while the number of medical institutions in China continues to rise, surgical technology is also boomi.
Because puncture instruments play an important role in establishing channels, the usage scenarios are gradually being broadened, and will be more used in minimally invasive surgery and newer diagnosis and treatment scenarios in the futu.
In summary, it is expected that the market space in this field will further increa.
In the research report of Kindly, a leading listed company in the domestic injection and puncture industry released by Huaan Securities, it is mentioned that injection and puncture consumables are a large category of low-value consumabl.According to the "Blue Book of Medical Devices in China (2021 Edition)" released by Medical Equipment Exchange, from 2018 to 2020, the market scale of low-value medical consumables in China will be 61 billion yuan, 77 billion yuan and 97 billion yuan respectively, of which injection and puncture products are in the low-value catego.
The medical consumables market accounts for the largest share, with a market share of 2
The scale in 2020 is about 22 billion yuan, and the compound annual growth rate from 2015 to 2020 is about 1
Looking forward to the future, the number of resident diagnoses will continue to increase, and new clinical applications and consumer-level application scenarios will increase, which will continue to drive the growth in demand for injection and puncture consumabl.
At the same time, Debon Securities mentioned in the research report that while the number of medical institutions in China continues to rise, surgical technology is also boomi.
Because puncture instruments play an important role in establishing channels, the usage scenarios are gradually being broadened, and will be more used in minimally invasive surgery and newer diagnosis and treatment scenarios in the futu.
In summary, it is expected that the market space in this field will further increa.
According to the "Blue Book of Medical Devices in China (2021 Edition)" released by Medical Equipment Exchange, from 2018 to 2020, the market scale of low-value medical consumables in China will be 61 billion yuan, 77 billion yuan and 97 billion yuan respectively, of which injection and puncture products are in the low-value catego.
The medical consumables market accounts for the largest share, with a market share of 2
The scale in 2020 is about 22 billion yuan, and the compound annual growth rate from 2015 to 2020 is about 1
Looking forward to the future, the number of resident diagnoses will continue to increase, and new clinical applications and consumer-level application scenarios will increase, which will continue to drive the growth in demand for injection and puncture consumabl.
At the same time, Debon Securities mentioned in the research report that while the number of medical institutions in China continues to rise, surgical technology is also boomi.
Because puncture instruments play an important role in establishing channels, the usage scenarios are gradually being broadened, and will be more used in minimally invasive surgery and newer diagnosis and treatment scenarios in the futu.
In summary, it is expected that the market space in this field will further increa.
The first kick-off meeting of "Kehuang Capsules for the Treatment of Non-Alcoholic Fatty Liver Disease" was successfully held in Zhengzhou
